BioSpace News Archive

Treadwell Therapeutics, a clinical-stage biotechnology company developing novel, cross-modality medicines for unmet needs in cancer, announced the initiation of patient dosing in TWT-202, its Phase 1b/2 study to evaluate its CFI-400945, an oral, first-in-class inhibitor of Polo-like kinase 4 in patients with Leukemia as a monotherapy or in combination with hypomethylating agents.

Dicerna Pharmaceuticals, Inc., a leading developer of investigational ribonucleic acid interference therapeutics, announced that the Company will release its first quarter 2021 financial results after market close on Thursday, May 6, 2021.

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced it plans to release its first quarter 2021 financial results after the market closes on Thursday, May 13, 2021.

DexCom, Inc. reported its financial results as of and for the quarter ended March 31, 2021.

“We have made strong progress in this first quarter, with our new partnership with Merck in long-acting HIV therapies, two newly approved indications in the U.S. for Trodelvy in metastatic triple-negative breast cancer and metastatic urothelial cancer, and the addition of Hepcludex to our portfolio,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences.

Intersect ENT, Inc., a global ear, nose and throat medical technology leader dedicated to transforming patient care, announced that the Company has changed the date of its previously scheduled first quarter 2021 financial results announcement and conference call.

Significant Regulatory Progress Across Diverse Oncology Pipeline, Including European Commission Approval of TUKYSA, Multiple Applications Under Review Globally for PADCEV, and FDA Acceptance of Tisotumab Vedotin BLA

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced the pricing of a $500 million senior secured term loan B facility and a $60 million senior secured revolving facility.

Dyadic International, Inc. announced that it will report its financial results for quarter ended March 31, 2021 and host a corporate update conference call on Thursday, May 13, 2021.

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) today announced the addition of a new study arm in the ongoing global Phase 2 clinical program for ELX-02 for the treatment of cystic fibrosis (CF) in patients with at least one G542X allele.